Prevention and Treatment of Mycoplasma pneumoniae Requires Long-term Attention  

作　　者：Dawei Zhang Zhaomin Feng Quanyi Wang 

机构地区：[1]Department of Infectious Diseases,Fifth Medical Center of Chinese People's Liberation Army(PLA)General Hospital,National Clinical Research Center for Infectious Diseases,Beijing 100039,China [2]Beijing Center for Disease Prevention and Control,Beijing 100013,China [3]Beijing Research Center for Respiratory Infectious Diseases,Beijing 100013,China.

出　　处：《Infectious Diseases & Immunity》2024年第2期58-60,共3页感染性疾病与免疫（英文）

基　　金：the National Key R&D Program of China(2021ZD0114103);the Capital's Funds for Health Improvement and Research(2022-4G-30117).

摘　　要：Mycoplasma pneumoniae is a major etiological agent of communityacquired pneumonia that accounts for 10%to 40%of communityacquired pneumonia and exhibits distinct cyclic epidemic patterns that recur at 3-to 7-year intervals,[1-4] Nonpharmaceutical interventions(NPIs)against coronavirus disease 2019(COVID-19)that were used by countries worldwide during the pandemic significantly reduced the prevalence of M.pneumoniae.[5]After the lifting of COVID-19 pandemic restrictions,M.pneumoniae gradually grew globally.[6]To provide a better understanding of the growth of M.pneumoniae in 2023,we explored the hazards,incidence,diagnosis,and antibiotic resistance of M.pneumoniae.

关 键 词：diagnosis PNEUMONIAE LIFTING 

分 类 号：R563.1[医药卫生—呼吸系统]